NeuroNova Going to Newron via $19M Stock-based Deal
By Cormac Sheridan
Thursday, June 14, 2012
Newron Pharmaceuticals SpA is taking over NeuroNova AB in a stock-based deal valued at €15.4 million (US$19.4 million), which will add two clinical-stage programs to its pipeline of drugs for neurodegenerative disease and €16 million in fresh funding.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.